Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against ChemoCentryx, Inc. (NasdaqGS: CCXI).
ChemoCentryx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 4, 2021, the U.S. Food and Drug Administration issued briefing documents regarding the Company’s drug candidate, avacopan, noting that “[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan” and that the review had “identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results.”
On this news, shares of ChemoCentryx plummeted approximately 45%, to close at $26.63 per share on May 4, 2021.
If you purchased shares of ChemoCentryx and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (firstname.lastname@example.org), or fill out the form on this page.